Citius Oncology (NASDAQ:CTOR – Get Free Report) is one of 844 public companies in the “Biotechnology” industry, but how does it contrast to its rivals? We will compare Citius Oncology to related companies based on the strength of its institutional ownership, risk, valuation, profitability, analyst recommendations, dividends and earnings.
Analyst Ratings
This is a breakdown of recent recommendations for Citius Oncology and its rivals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Citius Oncology | 1 | 0 | 0 | 0 | 1.00 |
| Citius Oncology Competitors | 9774 | 15034 | 45256 | 1571 | 2.54 |
As a group, “Biotechnology” companies have a potential upside of 95.72%. Given Citius Oncology’s rivals stronger consensus rating and higher possible upside, analysts plainly believe Citius Oncology has less favorable growth aspects than its rivals.
Volatility and Risk
Citius Oncology has a beta of 3.57, indicating that its share price is 257% more volatile than the S&P 500. Comparatively, Citius Oncology’s rivals have a beta of 1.14, indicating that their average share price is 14% more volatile than the S&P 500.
Earnings & Valuation
This table compares Citius Oncology and its rivals top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Citius Oncology | N/A | -$24.76 million | -1.18 |
| Citius Oncology Competitors | $722.78 million | $12.25 million | -10.11 |
Citius Oncology’s rivals have higher revenue and earnings than Citius Oncology. Citius Oncology is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Profitability
This table compares Citius Oncology and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Citius Oncology | N/A | -102.98% | -43.49% |
| Citius Oncology Competitors | -9,054.29% | -198.66% | -30.54% |
Insider & Institutional Ownership
70.5% of Citius Oncology shares are held by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are held by institutional investors. 9.8% of Citius Oncology shares are held by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
Citius Oncology rivals beat Citius Oncology on 8 of the 13 factors compared.
About Citius Oncology
Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.
Receive News & Ratings for Citius Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Citius Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png){kind=logo}
